Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10549-023-07171-z.pdf
Reference37 articles.
1. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A et al (2022) Breast cancer statistics. CA 72(6):524–541
2. Knape N, Park JH, Agala CB, Spanheimer P, Morrow M, Downs-Canner S et al (2023) Can we forgo sentinel lymph node biopsy in women aged ≥ 50 years with early-stage hormone-receptor-positive HER2-negative special histologic subtype breast cancer? Ann Surg Oncol 30(2):1042–1050. https://doi.org/10.1245/s10434-022-12626-6
3. Burguin A, Diorio C, Durocher F (2021) Breast cancer treatments: updates and new challenges. J Pers Med 11(8):808. https://doi.org/10.3390/jpm11080808
4. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al (2017) Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122–131. https://doi.org/10.1056/NEJMoa1703643
5. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752. https://doi.org/10.1200/jco.2014.55.5730
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3